CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Creso Pharma Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Creso Pharma Ltd
Tower 3, L 24 300 Barangaroo Avenue
Phone: +61 280678606p:+61 280678606 NSW  2000  Australia Ticker: CPHCPH

Business Summary
Creso Pharma Limited is an Australia-based company engaged in developing cannabis and hemp-derived therapeutic-grade Nutraceuticals and Medical Cannabis products with a range of applications in both human and animal health. The Company's principal activity is to develop, register and commercialize pharmaceutical-grade cannabis and hemp-based nutraceutical products and treatments. The Company's segments include Hemp-Industries s.r.o. (Hemp-Industries), which includes hemp-growing operations, outsourced cannabidiol (CBD) extraction and CBD product sales activities; Creso Pharma Switzerland GmbH (Switzerland), which includes the development and commercialization of its therapeutic products, and Creso Pharma Limited (Creso), which includes the Company's corporate administration. The Company primarily offers human health and animal health products, and hemp-derived extracts, oils and proteins.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
YesYes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/201912/31/2018Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board BoazWachtel 8/9/2017 8/9/2017
Chief Operating Officer DavidRussell 4/4/2017 4/4/2017
Managing Director, Executive Director Miriam H.Wernli
6 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 137,850,384 (As of 6/30/2019)
Stock Exchange: ASX
Fax Number: +61 894814950


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, December 14, 2019